and gives particular focus to nonalcoholic steatohepatitis (NASH). The downstream mechanisms by which endocrine disturbances cause liver disease might be similar to those involved in the ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

Tirzepatide may be more effective than semaglutide or liraglutide for weight loss, as it has a dual mechanism of action.

Sokal and Najimi discovered liver ... act on the mechanisms of cirrhosis, fibrosis, and control the acute and sub chronic inflammation that respectively contributes to ACLF and NASH.

GLP-1s like semaglutide and tirzepatide show promising MASH ... Madrigal believes that Rezdiffra's “fast” onset and “liver-directed” mechanism differentiates it from GLP-1s.